Perspective Therapeutics reports Q3 2025 net loss of $26.0M; cash $174M into late 2026

Perspective Therapeutics, Inc.

2025-Q3 EPS reported -$0.89 vs consensus -$0.33 ▼ miss (-167.4%)

Net loss $26.0M ($0.35/sh) vs $15.1M ($0.21) in Q3 2024; R&D spend $20.3M up 69% YoY.
Cash $174M as of Sep 30, 2025, down from $227M at Dec 31, 2024; runway into late 2026.
Clinical: VMT-α-NET cohort 3 opened June 2025, 8 patients enrolled; favorable safety in 55 patients.
VMT01 melanoma: 5 patients dosed at 3.0 mCi (monotherapy or +nivolumab) as of Oct 31, 2025.
PSV359 FAP-α therapy: 3 patients treated as of Oct 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.